Bench to Bedside®: MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
Bench to Bedside®: MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes is organized by Physicians' Education Resource, LLC (PER).
Release Date: January 24, 2023
Expiration Date: January 24, 2024
Description:
This online, on-demand virtual symposium brings together renowned experts in the use of minimal residual disease (MRD) assessment in decision-making for hematologic malignancies. In this educational program, experts use a case-based format to discuss the latest data regarding management of these disorders, share their perspectives and best practices, and forecast applications of MRD assessment in acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL).
This educational activity is an archive of the live symposium held on December 9, 2022.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain best practices in the assessment of MRD across hematologic malignancies, including the techniques and platforms
• Determine guideline recommendations and expert consensus to inform the use of MRD monitoring in hematologic malignancies’ settings
• Analyze the role of MRD assessment when planning treatment across the continuum of care for hematologic malignancies
• Formulate plans to integrate emerging data, sampling techniques, MRD assessment, and clinical trial data into the management of patients with hematologic malignancies.